Related Experiment Video

Updated: May 12, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

SYK regulates mTOR signaling in AML

J Carnevale1, L Ross, A Puissant

  • 1Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, MA, USA.

Leukemia
|March 29, 2013
PubMed

Insights

Spleen tyrosine kinase (SYK) regulates key signaling pathways in acute myeloid leukemia (AML). Inhibiting SYK impacts mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) pathways, affecting AML cell growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Spleen tyrosine kinase (SYK) is a novel target in acute myeloid leukemia (AML).
  • The precise role of SYK in AML pathogenesis remains unclear.
  • Prior studies suggest SYK interacts with mammalian target of rapamycin (mTOR) signaling in lymphoma.

Purpose of the Study:

  • To investigate the mechanistic role of SYK in AML.
  • To determine if SYK regulates mTOR signaling in AML.
  • To explore the impact of SYK inhibition on AML cell viability and differentiation.

Main Methods:

  • Utilized small-molecule SYK inhibitors and SYK-directed shRNA in AML models.
  • Assessed the effects of SYK inhibition on mTOR, AKT, PI3K, MAPK, MEK, and ERK signaling.
  • Evaluated changes in AML cell viability and differentiation following pathway modulation.

Main Results:

  • SYK inhibition suppressed mTOR and its downstream effectors, including AKT.
  • Combined SYK and PI3K pathway inhibition synergistically enhanced anti-leukemic effects.
  • Observed heterogeneous MAPK pathway responses, with RAS-mutated AML showing paradoxical MEK/ERK phosphorylation increases.

Conclusions:

  • SYK acts as a regulator of both mTOR and MAPK signaling cascades in AML.
  • Targeting the PI3K pathway potentiates the therapeutic effects of SYK inhibition in AML.
  • Understanding SYK's role offers potential new therapeutic strategies for AML treatment.

More Related Videos

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...